Does Nicotine Cause Cancer or Promote Its Growth?

Nicotine is not classified as a carcinogen by major health agencies, and on its own it does not appear to initiate cancer the way tobacco smoke’s dozens of other chemicals do. But calling it harmless would be badly misleading. A large and growing body of lab and animal research shows that nicotine actively promotes tumor growth, helps cancer spread, shields tumors from chemotherapy, and weakens the immune system’s ability to fight malignant cells. The distinction between “causing” cancer and “promoting” it matters a great deal in science, yet for someone already living with cancer or at high risk, the practical consequences overlap more than the labels suggest.

How Nicotine Helps Tumors Grow

Nicotine exerts most of its tumor-promoting effects by binding to nicotinic acetylcholine receptors on cell surfaces. These receptors are best known for their role in the nervous system, but they also sit on the surface of many cancer cells. When nicotine docks with them, it triggers signaling cascades inside the cell that push the cell to divide and survive longer than it normally would. In lung cancer specifically, a receptor subtype called alpha-7 nicotinic acetylcholine receptor is responsible for the proliferative and pro-metastatic effects of nicotine.¹ Activation of these receptors feeds into downstream pathways that promote cell survival, migration, and invasion, and this receptor-driven signaling has been linked not only to cancer progression but also to drug resistance.²

The same receptor-driven mechanism operates in cancers beyond the lung. In pancreatic cancer cells, nicotine enhanced proliferation, migration, and invasion, and in a mouse model of pancreatic cancer, nicotine-treated animals developed larger tumors with more nodules.³ In bladder cancer cells, nicotine exposure at moderate concentrations boosted cell viability to roughly 127 to 143 percent of untreated controls, and the effect ran through the same kind of growth-promoting signaling pathway.⁴ Breast cancer research tells a similar story: nicotine promotes angiogenesis, proliferation, and epithelial-mesenchymal transition while also boosting cancer stem cell populations.⁵ The pattern is consistent across tissue types: wherever cancer cells carry these receptors, nicotine can switch on growth signals.

Building a Blood Supply for Tumors

Tumors cannot grow beyond a tiny size without recruiting new blood vessels to feed them, a process called angiogenesis. Nicotine accelerates this process. In one well-studied mouse model of lung cancer, nicotine exposure was associated with a roughly fivefold increase in the density of tiny blood vessels within tumor nodules, and the researchers attributed the faster tumor growth primarily to this vascular boost rather than a direct effect on the cancer cells themselves.⁶

A separate set of experiments reinforced that finding. When colon cancer cells were implanted in mice, nicotine markedly accelerated tumor growth in the animals but did not increase cancer cell proliferation in a dish. The tumors in nicotine-exposed mice were more heavily vascularized, and bone-marrow-derived cells contributed to the new blood vessels.⁷ The implication is striking: even when nicotine does not make cancer cells divide faster in isolation, it can still make tumors grow faster by ensuring they get the blood supply they need.

Making Cancer Cells More Invasive

One of the scariest things a cancer cell can do is change its behavior from a stationary, tissue-bound cell into a mobile one that can invade surrounding tissue and eventually metastasize. This identity shift is called epithelial-mesenchymal transition, and nicotine can trigger it. In human bronchial epithelial cells, nicotine activated a signaling pathway that caused cells to lose their normal sticky connections to neighbors and gain characteristics of mesenchymal cells: increased movement, changes in structural proteins, and production of enzymes that degrade surrounding tissue.⁸

Long-term exposure to e-cigarette liquids and aerosols produced a similar transformation in lung cancer cells, which took on a fibroblast-like shape, lost their cell-to-cell junctions, and became more mobile.⁹ In head and neck cancer cells, nicotine treatment upregulated markers associated with stem-like, self-renewing behavior, which overlaps heavily with the invasive phenotype.¹⁰ In short, nicotine does not merely keep tumors alive and fed; it nudges cancer cells toward a more aggressive, harder-to-treat state.

Weakening the Immune Defense Against Tumors

Your immune system is one of your main lines of defense against cancer. Certain white blood cells, particularly a type called CD8+ T cells, are responsible for recognizing and killing tumor cells. Nicotine appears to blunt this defense. Research on lung cancer cells showed that nicotine pushed CD8+ T cells into an “exhausted” state, reducing their levels of a key cell-killing enzyme called granzyme B. When these nicotine-exposed immune cells were tested in a humanized mouse tumor model, they were less effective at controlling tumor growth.¹¹

E-cigarette aerosol exposure in a tumor mouse model amplified these immunosuppressive effects further. Mice exposed to aerosolized e-cigarette liquids and then inoculated with tumor cells showed reduced survival, increased tumor growth, and higher numbers of metastatic lung nodules compared to air-exposed controls. The T cells in these animals accumulated immune checkpoint markers associated with impaired function.¹² The upshot is that nicotine may handicap exactly the immune mechanisms that modern immunotherapy drugs are designed to unleash.

Interfering with Cancer Treatment

For patients already undergoing cancer treatment, the evidence on nicotine is particularly troubling. Nicotine has been shown to inhibit apoptosis, the process of programmed cell death that chemotherapy drugs rely on to kill cancer cells. In non-small cell lung cancer lines, nicotine blocked cell death induced by three widely used chemotherapy agents: gemcitabine, cisplatin, and taxol. The protection worked by boosting levels of two anti-apoptotic proteins inside the cells.¹³

This anti-apoptotic effect is not limited to lung cancer. In gastric cancer cells, nicotine protected against cisplatin-induced death, and blocking the relevant receptor or its downstream signaling restored the cancer cells’ vulnerability to the drug.¹⁴ In nasal epithelial cancer, nicotine partially inhibited apoptosis from a cisplatin-etoposide combination.¹⁵ In breast cancer cells, nicotine produced chemoresistance effects that the researchers attributed to promotion of cancer stem cell populations.¹⁶ A review of the field concluded that nicotine can decrease the effectiveness of both chemotherapy and radiotherapy through receptor-mediated signaling that promotes tumor progression and treatment resistance.¹⁷

The clinical implications are real. A cancer patient who continues using nicotine-containing products during treatment may be undermining the very drugs that are meant to save their life. This holds whether the nicotine comes from cigarettes, a vape, a patch, or gum, though the magnitude of the effect from cleaner nicotine sources is harder to pin down in humans.

Can Nicotine Actually Damage DNA?

Here is where the traditional line between “not a carcinogen” and “promotes cancer” gets blurrier. Classic carcinogens initiate cancer by directly damaging DNA, and for decades nicotine was thought to be largely innocent on that front. But newer research has complicated the picture. One finding that drew attention is that nicotine can be converted inside mouse and human cells into nitrosamines, the same class of potent carcinogens found in tobacco smoke. These nitrosamines then create DNA adducts, which are chemical modifications that can lead to mutations, and simultaneously inhibit DNA repair.¹⁸ The tobacco-specific nitrosamines NNK and NNN, which can be formed from nicotine, induce mutations in oncogenes and tumor suppressor genes while also binding to nicotinic acetylcholine receptors to promote tumor growth.¹⁹

Beyond direct DNA damage, nicotine also affects the epigenetic machinery that controls which genes are turned on or off. In normal pancreatic ductal cells, nicotine caused overexpression of enzymes that add methyl groups to DNA, leading to the silencing of tumor suppressor genes. This happened through the alpha-7 nicotinic receptor.²⁰ In bladder cancer cells, chronic nicotine exposure led to overexpression of a protein that drives cell division, along with cell cycle disruptions.²¹

Whether these mechanisms are potent enough to initiate cancer in humans at the doses delivered by nicotine products remains an open question. The endogenous nitrosation pathway, for instance, generates far less carcinogenic material than inhaling combusted tobacco smoke. Still, the old reassurance that nicotine “isn’t carcinogenic” now requires a significant asterisk. It may not be a classic direct-acting carcinogen, but it is not inert toward DNA either.

Cancer Stem Cells and Self-Renewal

Cancer stem cells are the subpopulation of tumor cells with the ability to self-renew and regenerate a tumor after treatment. They are a major reason cancers come back. Nicotine appears to expand this dangerous subpopulation. In non-small cell lung cancer, nicotine and e-cigarette extracts both enhanced sphere formation and self-renewal of cancer stem cells, and the effect depended on the protein Sox2. When Sox2 was depleted, the nicotine-driven self-renewal was abolished.²²

Recent research has also identified a molecular pathway through which nicotine stabilizes a key protein and enables it to drive the expression of a gene involved in proliferation and metastasis of lung cancer cells. Inhibiting this downstream target with small molecules significantly reduced the nicotine-driven proliferative and metastatic effects.²³ These findings matter because they identify specific points where drugs might eventually be able to block nicotine’s cancer-promoting effects.

Is Nicotine Replacement Therapy Safe for Cancer Risk?

Given everything above, you might reasonably wonder whether nicotine patches, gums, and lozenges used to quit smoking carry a cancer risk. The reassuring answer is that the best available human evidence says they do not. A systematic review looking for serious adverse health effects of nicotine replacement therapy found only one high-quality long-term study, the Lung Health Study follow-up. It tracked more than 3,300 participants over roughly twelve and a half years. After adjusting for age, sex, and smoking history, nicotine gum use was unrelated to lung cancer, gastrointestinal cancer, or cancer overall. In contrast, continued cigarette smoking was significantly related to lung cancer risk.²⁴

The caveat is that very long-term studies of nicotine replacement therapy effects on cancer simply do not yet exist, and definitive answers would require them.²⁵ The practical takeaway is clear, though: using nicotine replacement to quit smoking is far, far safer than continuing to smoke. Cigarette smoke delivers thousands of toxic chemicals alongside nicotine. Removing the combustion and the tar while keeping the nicotine dramatically cuts exposure to known carcinogens, even if nicotine itself has tumor-promoting properties in the lab.

E-Cigarettes, Vaping, and Oral Nicotine Products

E-cigarettes sit in a more uncertain space. They deliver nicotine without combustion, but they also produce an aerosol that contains other potentially harmful substances. A systematic review of the cancer-related evidence found mixed results across cell, animal, and human studies. Multiple cell studies showed increased oxidative stress and genotoxicity from nicotine-containing e-cigarette aerosol, and some animal work found DNA damage, particularly from high-powered devices. One rodent inhalation study reported that e-cigarette aerosol exposure caused lung adenocarcinomas in mice.²⁶ However, other cell studies found no significant DNA damage or genotoxic effects, and one even suggested decreased susceptibility to carcinogenesis after acute exposure.²⁷

Where the evidence is more consistent is on metastasis. Animal model work has shown that e-cigarette exposure promotes tumor invasion, metastasis, and immunosuppression, with increased immune checkpoint markers on T cells. These effects could be partially mitigated by immune checkpoint blockade therapy, suggesting the components of e-cigarettes are not direct carcinogens so much as tumor promoters and immune suppressors.²⁸

Tobacco-free nicotine pouches, a newer category, contain a cellulose matrix with nicotine but no tobacco leaf. Chemical analysis suggests they expose users to lower levels of toxic compounds than Swedish snus, which itself is associated with significantly fewer health risks than cigarette smoking. Researchers have placed nicotine pouches close to medicinal nicotine replacement products on the harm continuum, though long-term data are still lacking.²⁹

The Gut Microbiome Connection

An emerging area of research connects nicotine and smoking to cancer through changes in the gut microbiome. Smoking is associated with significant shifts in intestinal microbial composition, and the disruption appears to worsen with heavier tobacco exposure.³⁰ In a striking experiment, researchers transplanted gut bacteria from smoke-exposed mice into mice with depleted microbiomes and then implanted pancreatic cancer tumors. The mice that received the smoker-derived microbiome developed significantly larger tumors than those that received bacteria from smoke-free donors.³¹ This suggests that some of nicotine and tobacco’s cancer-promoting effects may be indirect, mediated by the community of microbes living in your gut.

Early Life Exposure

The question of whether nicotine exposure during pregnancy or early childhood affects cancer risk deserves its own mention. Animal studies suggest that nicotine alone, separated from the other chemicals in tobacco smoke, may be a key chemical responsible for many of the long-term effects associated with maternal cigarette smoking, including an increased risk of cancer in offspring.³² The developing body is especially vulnerable because its cells are dividing rapidly and its detoxification systems are immature. This is one reason clinicians are cautious about nicotine replacement therapy during pregnancy, even though it avoids the combustion products of cigarettes.

Why Public Perception Gets This Wrong in Both Directions

The relationship between nicotine and cancer is widely misunderstood, and the misunderstanding cuts two ways. A majority of adults who smoke in the United States incorrectly believe that nicotine itself causes cancer. This belief acts as a barrier to switching from cigarettes to less harmful nicotine products: if you think nicotine is the cancer-causing ingredient, there is no perceived benefit to switching to a patch or a vape. The science is clear that inhaling the smoke from burning tobacco is responsible for the vast majority of smoking-related cancer, and removing combustion drastically reduces risk even when nicotine delivery continues.³³

At the same time, a growing body of evidence shows that nicotine is not simply a bystander addictive molecule. It promotes tumor growth, angiogenesis, metastasis, treatment resistance, and immune evasion across a range of cancer types, at least in laboratory and animal models. The danger of overcorrecting, of telling people nicotine is “perfectly safe” as long as it is not in a cigarette, is that it ignores these real biological effects. For someone without cancer who is trying to quit smoking, the calculus is overwhelmingly in favor of nicotine replacement. For someone already diagnosed with cancer, the evidence that nicotine can undermine treatment and accelerate progression adds urgency to the conversation about quitting all nicotine products, not just cigarettes.